FY2025 EPS Forecast for Exact Sciences Increased by Analyst

Exact Sciences Corporation (NASDAQ:EXAS) – William Blair increased their FY2025 EPS estimates for shares of Exact Sciences in a report released on Wednesday, September 10th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings per share of $0.36 for the year, up from their previous forecast of $0.22. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences’ Q4 2025 earnings at $0.20 EPS.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $811.09 million during the quarter, compared to analysts’ expectations of $774.43 million. During the same quarter last year, the company posted ($0.09) EPS. The firm’s revenue was up 16.0% compared to the same quarter last year.

Several other brokerages have also recently commented on EXAS. Craig Hallum raised their price target on shares of Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. Royal Bank Of Canada decreased their price target on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a research report on Thursday, August 7th. BTIG Research reduced their price objective on shares of Exact Sciences from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. UBS Group reduced their price objective on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, August 7th. Finally, Zacks Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $68.05.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $52.94 on Monday. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. Exact Sciences has a 52 week low of $38.81 and a 52 week high of $72.83. The stock has a market capitalization of $10.02 billion, a PE ratio of -9.75, a P/E/G ratio of 4.93 and a beta of 1.05. The firm has a 50 day moving average of $48.87 and a two-hundred day moving average of $49.36.

Insider Buying and Selling

In related news, Director James Edward Doyle sold 1,485 shares of Exact Sciences stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $42.02, for a total transaction of $62,399.70. Following the sale, the director directly owned 59,962 shares in the company, valued at $2,519,603.24. This trade represents a 2.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Exact Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in Exact Sciences by 463.0% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 1,216 shares of the medical research company’s stock worth $65,000 after acquiring an additional 1,000 shares in the last quarter. Forefront Wealth Partners LLC acquired a new stake in Exact Sciences during the 2nd quarter worth $208,000. Marex Group plc acquired a new stake in Exact Sciences during the 2nd quarter worth $341,000. Geneos Wealth Management Inc. raised its stake in Exact Sciences by 68.6% during the 2nd quarter. Geneos Wealth Management Inc. now owns 1,915 shares of the medical research company’s stock worth $102,000 after acquiring an additional 779 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in Exact Sciences by 28.9% during the 2nd quarter. Corient Private Wealth LLC now owns 16,737 shares of the medical research company’s stock worth $889,000 after acquiring an additional 3,748 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.